Dupilumab as monotherapy for bullous pemphigoid with multiple underlying diseases: A report of two cases

Indian J Dermatol Venereol Leprol. 2023 Nov-Dec;89(6):888-890. doi: 10.25259/IJDVL_1149_2022.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Humans
  • Pemphigoid, Bullous*

Substances

  • dupilumab
  • Antibodies, Monoclonal, Humanized